Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock

Posted by Brenda Bartman on Jul 2nd, 2026

Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $91.40, for a total transaction of $56,576.60. Following the transaction, the vice president owned 40,411 shares in the company, valued at $3,693,565.40. This represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Up 1.7%

Shares of Edwards Lifesciences stock opened at $91.95 on Thursday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The firm has a market cap of $52.95 billion, a price-to-earnings ratio of 48.91, a price-to-earnings-growth ratio of 2.27 and a beta of 0.85. The business has a fifty day simple moving average of $85.06 and a 200-day simple moving average of $83.41. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $92.88.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter last year, the business posted $0.64 earnings per share. The company’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EW. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Evercore restated an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Barclays reiterated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $96.39.

Get Our Latest Analysis on Edwards Lifesciences

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $266,000. NewEdge Advisors LLC increased its position in Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. increased its position in Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after purchasing an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after purchasing an additional 1,065 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.